Skip to main content
Erschienen in: Basic Research in Cardiology 5/2012

01.09.2012 | Original Contribution

Constitutive phosphorylation of inhibitor-1 at Ser67 and Thr75 depresses calcium cycling in cardiomyocytes and leads to remodeling upon aging

verfasst von: Stela Florea, Ahmad Anjak, Wen-Feng Cai, Jiang Qian, Elizabeth Vafiadaki, Sarah Figueria, Kobra Haghighi, Jack Rubinstein, John Lorenz, Evangelia G. Kranias

Erschienen in: Basic Research in Cardiology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

The activity of protein phosphatase-1 (PP1) inhibitor-1 (I-1) is antithetically modulated by the cAMP-protein kinase A (PKA) and Ca2+-protein kinase C (PKC) signaling axes. β-adrenergic (β-AR) stimulation results in PKA-phosphorylation of I-1 at threonine 35 (Thr35) and depressed PP1 activity, while PKC phosphorylation at serine 67 (Ser67) and/or Thr75 increases PP1 activity. In heart failure, pThr35 is decreased while pSer67 and pThr75 are elevated. However, the role of Ser67/Thr75 phosphorylation in vivo and its effects on Ca2+-cycling are not known. Thus, our aim was to investigate the functional significance of Ser67 and Thr75 phosphorylation in intact hearts. We generated transgenic mice (TG) with cardiac-specific overexpression of constitutively phosphorylated I-1 at Ser67 and Thr75 (S67D/T75D) and evaluated cardiac function. The S67D/T75D cardiomyocytes exhibited significantly depressed Ca2+-kinetics and contractile parameters, compared with wild-type (WT) cells. The decreased Ca2+-cycling was associated with a 27 % increase in PP1 activity, no alterations in PP2 activity and impaired phosphorylation of myosin-binding protein-C (MyBPC). Upon aging, there was cardiac remodeling associated with increases in systolic and diastolic left ventricular internal diameter dimensions (at 16 months), compared with WTs. The results indicate that phosphorylation of I-1 at Ser67 and Thr75 is associated with increased PP1 activity and depressed cardiomyocyte Ca2+-cycling, which manifests in geometrical alterations over the long term. Thus, hyperphosphorylation of these sites in failing hearts may contribute to deteriorative remodeling.
Literatur
3.
Zurück zum Zitat Anjak A, Koch SE, Jiang MV, Jones WK, Rubinstein J (2011) Age and gender related changes in myocardial function in wild type FVB/N mice evaluated by advanced echocardiography. JASE 24:B7 Anjak A, Koch SE, Jiang MV, Jones WK, Rubinstein J (2011) Age and gender related changes in myocardial function in wild type FVB/N mice evaluated by advanced echocardiography. JASE 24:B7
6.
Zurück zum Zitat Bowling N, Walsh RA, Song G, Estridge T, Sandusky GE, Fouts RL, Mintze K, Pickard T, Roden R, Bristow MR, Sabbah HN, Mizrahi JL, Gromo G, King GL, Vlahos CJ (1999) Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation 99:384–391. doi:10.1161/01.CIR.99.3.384 PubMedCrossRef Bowling N, Walsh RA, Song G, Estridge T, Sandusky GE, Fouts RL, Mintze K, Pickard T, Roden R, Bristow MR, Sabbah HN, Mizrahi JL, Gromo G, King GL, Vlahos CJ (1999) Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation 99:384–391. doi:10.​1161/​01.​CIR.​99.​3.​384 PubMedCrossRef
7.
Zurück zum Zitat Boyle AJ, Shih H, Hwang J, Ye J, Lee B, Zhang Y, Kwon D, Jun K, Zheng D, Sievers R, Angeli F, Yeghiazarians Y, Lee R (2011) Cardiomyopathy of aging in the mammalian heart is characterized by myocardial hypertrophy, fibrosis and a predisposition towards cardiomyocyte apoptosis and autophagy. Exp Gerontol 46:549–559. doi:10.1016/j.exger.2011.02.010 PubMedCrossRef Boyle AJ, Shih H, Hwang J, Ye J, Lee B, Zhang Y, Kwon D, Jun K, Zheng D, Sievers R, Angeli F, Yeghiazarians Y, Lee R (2011) Cardiomyopathy of aging in the mammalian heart is characterized by myocardial hypertrophy, fibrosis and a predisposition towards cardiomyocyte apoptosis and autophagy. Exp Gerontol 46:549–559. doi:10.​1016/​j.​exger.​2011.​02.​010 PubMedCrossRef
8.
Zurück zum Zitat Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, Kimball TF, Lorenz JN, Nairn AC, Liggett SB, Bodi I, Wang S, Schwartz A, Lakatta EG, DePaoli-Roach AA, Robbins J, Hewett TE, Bibb JA, Westfall MV, Kranias EG, Molkentin JD (2004) PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 10:248–254. doi:10.1038/nm1000 PubMedCrossRef Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, Kimball TF, Lorenz JN, Nairn AC, Liggett SB, Bodi I, Wang S, Schwartz A, Lakatta EG, DePaoli-Roach AA, Robbins J, Hewett TE, Bibb JA, Westfall MV, Kranias EG, Molkentin JD (2004) PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 10:248–254. doi:10.​1038/​nm1000 PubMedCrossRef
9.
Zurück zum Zitat Carr AN, Schmidt AG, Suzuki Y, del Monte F, Sato Y, Lanner C, Breeden K, Jing SL, Allen PB, Greengard P, Yatani A, Hoit BD, Grupp IL, Hajjar RJ, DePaoli-Roach AA, Kranias EG (2002) Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 22:4124–4135. doi:10.1128/MCB.22.12.4124-4135.2002 PubMedCrossRef Carr AN, Schmidt AG, Suzuki Y, del Monte F, Sato Y, Lanner C, Breeden K, Jing SL, Allen PB, Greengard P, Yatani A, Hoit BD, Grupp IL, Hajjar RJ, DePaoli-Roach AA, Kranias EG (2002) Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 22:4124–4135. doi:10.​1128/​MCB.​22.​12.​4124-4135.​2002 PubMedCrossRef
10.
Zurück zum Zitat Chen G, Zhou X, Florea S, Qian J, Cai W, Zhang Z, Fan GC, Lorenz J, Hajjar RJ, Kranias EG (2010) Expression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosis. Basic Res Cardiol 105:573–581. doi:10.1007/s00395-010-0106-3 PubMedCrossRef Chen G, Zhou X, Florea S, Qian J, Cai W, Zhang Z, Fan GC, Lorenz J, Hajjar RJ, Kranias EG (2010) Expression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosis. Basic Res Cardiol 105:573–581. doi:10.​1007/​s00395-010-0106-3 PubMedCrossRef
12.
Zurück zum Zitat El-Armouche A, Rau T, Zolk O, Ditz D, Pamminger T, Zimmermann WH, Jackel E, Harding SE, Boknik P, Neumann J, Eschenhagen T (2003) Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J 17:437–439. doi:10.1096/fj.02-0057fje PubMed El-Armouche A, Rau T, Zolk O, Ditz D, Pamminger T, Zimmermann WH, Jackel E, Harding SE, Boknik P, Neumann J, Eschenhagen T (2003) Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J 17:437–439. doi:10.​1096/​fj.​02-0057fje PubMed
13.
Zurück zum Zitat El-Armouche A, Wittkopper K, Fuller W, Howie J, Shattock MJ, Pavlovic D (2011) Phospholemman-dependent regulation of the cardiac Na/K-ATPase activity is modulated by inhibitor-1 sensitive type-1 phosphatase. FASEB J 25:4467–4475. doi:10.1096/fj.11-184903 PubMedCrossRef El-Armouche A, Wittkopper K, Fuller W, Howie J, Shattock MJ, Pavlovic D (2011) Phospholemman-dependent regulation of the cardiac Na/K-ATPase activity is modulated by inhibitor-1 sensitive type-1 phosphatase. FASEB J 25:4467–4475. doi:10.​1096/​fj.​11-184903 PubMedCrossRef
14.
Zurück zum Zitat Endo S, Zhou X, Connor J, Wang B, Shenolikar S (1996) Multiple structural elements define the specificity of recombinant human inhibitor-1 as a protein phosphatase-1 inhibitor. Biochemistry 35:5220–5228. doi:10.1021/bi952940f PubMedCrossRef Endo S, Zhou X, Connor J, Wang B, Shenolikar S (1996) Multiple structural elements define the specificity of recombinant human inhibitor-1 as a protein phosphatase-1 inhibitor. Biochemistry 35:5220–5228. doi:10.​1021/​bi952940f PubMedCrossRef
16.
Zurück zum Zitat Gupta RC, Neumann J, Watanabe AM, Lesch M, Sabbah HN (1996) Evidence for presence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocyte. Am J Physiol 270:H1159–H1164PubMed Gupta RC, Neumann J, Watanabe AM, Lesch M, Sabbah HN (1996) Evidence for presence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocyte. Am J Physiol 270:H1159–H1164PubMed
17.
18.
Zurück zum Zitat Herzig S, Neumann J (2000) Effects of serine/threonine protein phosphatases on ion channels in excitable membranes. Physiol Rev 80:173–210PubMed Herzig S, Neumann J (2000) Effects of serine/threonine protein phosphatases on ion channels in excitable membranes. Physiol Rev 80:173–210PubMed
20.
Zurück zum Zitat Hua Y, Zhang Y, Ceylan-Isik AF, Wold LE, Nunn JM, Ren J (2011) Chronic Akt activation accentuates aging-induced cardiac hypertrophy and myocardial contractile dysfunction: role of autophagy. Basic Res Cardiol 106:1173–1191. doi:10.1007/s00395-011-0222-8 PubMedCrossRef Hua Y, Zhang Y, Ceylan-Isik AF, Wold LE, Nunn JM, Ren J (2011) Chronic Akt activation accentuates aging-induced cardiac hypertrophy and myocardial contractile dysfunction: role of autophagy. Basic Res Cardiol 106:1173–1191. doi:10.​1007/​s00395-011-0222-8 PubMedCrossRef
21.
23.
Zurück zum Zitat Koch SE, Gao X, Haar L, Jiang M, Lasko VM, Robbins N, Cai W, Brokamp C, Varma P, Tranter M, Liu Y, Ren X, Lorenz JN, Wang HS, Jones WK, Rubinstein J (2012) Probenecid: a novel use as a non-injurious positive inotrope through cardiac TRPV2 stimulation. J Mol Cell Cardiol 53:134–144. doi:10.1016/j.yjmcc.2012.04.011 Koch SE, Gao X, Haar L, Jiang M, Lasko VM, Robbins N, Cai W, Brokamp C, Varma P, Tranter M, Liu Y, Ren X, Lorenz JN, Wang HS, Jones WK, Rubinstein J (2012) Probenecid: a novel use as a non-injurious positive inotrope through cardiac TRPV2 stimulation. J Mol Cell Cardiol 53:134–144. doi:10.​1016/​j.​yjmcc.​2012.​04.​011
24.
Zurück zum Zitat Kooij V, Boontje N, Zaremba R, Jaquet K, dos Remedios C, Stienen GJ, van der Velden J (2010) Protein kinase C alpha and epsilon phosphorylation of troponin and myosin binding protein C reduce Ca2+ sensitivity in human myocardium. Basic Res Cardiol 105:289–300. doi:10.1007/s00395-009-0053-z PubMedCrossRef Kooij V, Boontje N, Zaremba R, Jaquet K, dos Remedios C, Stienen GJ, van der Velden J (2010) Protein kinase C alpha and epsilon phosphorylation of troponin and myosin binding protein C reduce Ca2+ sensitivity in human myocardium. Basic Res Cardiol 105:289–300. doi:10.​1007/​s00395-009-0053-z PubMedCrossRef
25.
Zurück zum Zitat Linck B, Boknik P, Knapp J, Muller FU, Neumann J, Schmitz W, Vahlensieck U (1996) Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts. Br J Pharmacol 119:545–550PubMedCrossRef Linck B, Boknik P, Knapp J, Muller FU, Neumann J, Schmitz W, Vahlensieck U (1996) Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts. Br J Pharmacol 119:545–550PubMedCrossRef
27.
Zurück zum Zitat Neumann J (2002) Altered phosphatase activity in heart failure, influence on Ca2+ movement. Basic Res Cardiol 97(Suppl 1):I91–I95PubMed Neumann J (2002) Altered phosphatase activity in heart failure, influence on Ca2+ movement. Basic Res Cardiol 97(Suppl 1):I91–I95PubMed
28.
Zurück zum Zitat Neumann J, Boknik P, Herzig S, Schmitz W, Scholz H, Gupta RC, Watanabe AM (1993) Evidence for physiological functions of protein phosphatases in the heart: evaluation with okadaic acid. Am J Physiol 265:H257–H266PubMed Neumann J, Boknik P, Herzig S, Schmitz W, Scholz H, Gupta RC, Watanabe AM (1993) Evidence for physiological functions of protein phosphatases in the heart: evaluation with okadaic acid. Am J Physiol 265:H257–H266PubMed
30.
31.
Zurück zum Zitat Nicolaou P, Rodriguez P, Ren X, Zhou X, Qian J, Sadayappan S, Mitton B, Pathak A, Robbins J, Hajjar RJ, Jones K, Kranias EG (2009) Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res 104:1012–1020. doi:10.1161/CIRCRESAHA.108.189811 PubMedCrossRef Nicolaou P, Rodriguez P, Ren X, Zhou X, Qian J, Sadayappan S, Mitton B, Pathak A, Robbins J, Hajjar RJ, Jones K, Kranias EG (2009) Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res 104:1012–1020. doi:10.​1161/​CIRCRESAHA.​108.​189811 PubMedCrossRef
33.
Zurück zum Zitat Pathak A, del Monte F, Zhao W, Schultz JE, Lorenz JN, Bodi I, Weiser D, Hahn H, Carr AN, Syed F, Mavila N, Jha L, Qian J, Marreez Y, Chen G, McGraw DW, Heist EK, Guerrero JL, DePaoli-Roach AA, Hajjar RJ, Kranias EG (2005) Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 96:756–766. doi:10.1161/01.RES.0000161256.85833.fa PubMedCrossRef Pathak A, del Monte F, Zhao W, Schultz JE, Lorenz JN, Bodi I, Weiser D, Hahn H, Carr AN, Syed F, Mavila N, Jha L, Qian J, Marreez Y, Chen G, McGraw DW, Heist EK, Guerrero JL, DePaoli-Roach AA, Hajjar RJ, Kranias EG (2005) Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 96:756–766. doi:10.​1161/​01.​RES.​0000161256.​85833.​fa PubMedCrossRef
34.
Zurück zum Zitat Rodriguez P, Mitton B, Nicolaou P, Chen G, Kranias EG (2007) Phosphorylation of human inhibitor-1 at Ser67 and/or Thr75 attenuates stimulatory effects of protein kinase A signaling in cardiac myocytes. Am J Physiol Heart Circ Physiol 293:H762–H769. doi:10.1152/ajpheart.00104.2007 PubMedCrossRef Rodriguez P, Mitton B, Nicolaou P, Chen G, Kranias EG (2007) Phosphorylation of human inhibitor-1 at Ser67 and/or Thr75 attenuates stimulatory effects of protein kinase A signaling in cardiac myocytes. Am J Physiol Heart Circ Physiol 293:H762–H769. doi:10.​1152/​ajpheart.​00104.​2007 PubMedCrossRef
35.
Zurück zum Zitat Rodriguez P, Mitton B, Waggoner JR, Kranias EG (2006) Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function. J Biol Chem 281:38599–38608. doi:10.1074/jbc.M604139200 PubMedCrossRef Rodriguez P, Mitton B, Waggoner JR, Kranias EG (2006) Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function. J Biol Chem 281:38599–38608. doi:10.​1074/​jbc.​M604139200 PubMedCrossRef
37.
Zurück zum Zitat Sachan N, Dey A, Rotter D, Grinsfelder DB, Battiprolu PK, Sikder D, Copeland V, Oh M, Bush E, Shelton JM, Bibb JA, Hill JA, Rothermel BA (2011) Sustained hemodynamic stress disrupts normal circadian rhythms in calcineurin-dependent signaling and protein phosphorylation in the heart. Circ Res 108:437–445. doi:10.1161/CIRCRESAHA.110.235309 PubMedCrossRef Sachan N, Dey A, Rotter D, Grinsfelder DB, Battiprolu PK, Sikder D, Copeland V, Oh M, Bush E, Shelton JM, Bibb JA, Hill JA, Rothermel BA (2011) Sustained hemodynamic stress disrupts normal circadian rhythms in calcineurin-dependent signaling and protein phosphorylation in the heart. Circ Res 108:437–445. doi:10.​1161/​CIRCRESAHA.​110.​235309 PubMedCrossRef
38.
Zurück zum Zitat Sadayappan S, Gulick J, Osinska H, Barefield D, Cuello F, Avkiran M, Lasko VM, Lorenz JN, Maillet M, Martin JL, Brown JH, Bers DM, Molkentin JD, James J, Robbins J (2011) A critical function for Ser-282 in cardiac Myosin binding protein-C phosphorylation and cardiac function. Circ Res 109:141–150. doi:10.1161/CIRCRESAHA.111.242560 PubMedCrossRef Sadayappan S, Gulick J, Osinska H, Barefield D, Cuello F, Avkiran M, Lasko VM, Lorenz JN, Maillet M, Martin JL, Brown JH, Bers DM, Molkentin JD, James J, Robbins J (2011) A critical function for Ser-282 in cardiac Myosin binding protein-C phosphorylation and cardiac function. Circ Res 109:141–150. doi:10.​1161/​CIRCRESAHA.​111.​242560 PubMedCrossRef
40.
Zurück zum Zitat Sadayappan S, Osinska H, Klevitsky R, Lorenz JN, Sargent M, Molkentin JD, Seidman CE, Seidman JG, Robbins J (2006) Cardiac myosin binding protein C phosphorylation is cardioprotective. Proc Natl Acad Sci USA 103:16918–16923. doi:10.1073/pnas.0607069103 PubMedCrossRef Sadayappan S, Osinska H, Klevitsky R, Lorenz JN, Sargent M, Molkentin JD, Seidman CE, Seidman JG, Robbins J (2006) Cardiac myosin binding protein C phosphorylation is cardioprotective. Proc Natl Acad Sci USA 103:16918–16923. doi:10.​1073/​pnas.​0607069103 PubMedCrossRef
41.
Zurück zum Zitat Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, Gerst M, Young K, Hoit BD, McConnell BK, Haghighi K, Seidman CE, Seidman JG, Dorn GW 2nd, Kranias EG (2003) Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest 111:859–867. doi:10.1172/JCI16738 PubMed Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, Gerst M, Young K, Hoit BD, McConnell BK, Haghighi K, Seidman CE, Seidman JG, Dorn GW 2nd, Kranias EG (2003) Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest 111:859–867. doi:10.​1172/​JCI16738 PubMed
42.
43.
Zurück zum Zitat Totzeck A, Boengler K, van de Sand A, Konietzka I, Gres P, Garcia-Dorado D, Heusch G, Schulz R (2008) No impact of protein phosphatases on connexin 43 phosphorylation in ischemic preconditioning. Am J Physiol Heart Circ Physiol 295:H2106–H2112. doi:10.1152/ajpheart.00456.2008 PubMedCrossRef Totzeck A, Boengler K, van de Sand A, Konietzka I, Gres P, Garcia-Dorado D, Heusch G, Schulz R (2008) No impact of protein phosphatases on connexin 43 phosphorylation in ischemic preconditioning. Am J Physiol Heart Circ Physiol 295:H2106–H2112. doi:10.​1152/​ajpheart.​00456.​2008 PubMedCrossRef
44.
Zurück zum Zitat Wang J, Liu X, Sentex E, Takeda N, Dhalla NS (2003) Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol 284:H2277–H2287. doi:10.1152/ajpheart.00142.200 PubMed Wang J, Liu X, Sentex E, Takeda N, Dhalla NS (2003) Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol 284:H2277–H2287. doi:10.​1152/​ajpheart.​00142.​200 PubMed
45.
Zurück zum Zitat Wittkopper K, Dobrev D, Eschenhagen T, El-Armouche A (2011) Phosphatase-1 inhibitor-1 in physiological and pathological beta-adrenoceptor signalling. Cardiovasc Res 91:392–401. doi:10.1093/cvr/cvr058 PubMedCrossRef Wittkopper K, Dobrev D, Eschenhagen T, El-Armouche A (2011) Phosphatase-1 inhibitor-1 in physiological and pathological beta-adrenoceptor signalling. Cardiovasc Res 91:392–401. doi:10.​1093/​cvr/​cvr058 PubMedCrossRef
47.
Zurück zum Zitat Wittkopper K, Fabritz L, Neef S, Ort KR, Grefe C, Unsold B, Kirchhof P, Maier LS, Hasenfuss G, Dobrev D, Eschenhagen T, El-Armouche A (2010) Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J Clin Invest 120:617–626. doi:10.1172/JCI40545 PubMed Wittkopper K, Fabritz L, Neef S, Ort KR, Grefe C, Unsold B, Kirchhof P, Maier LS, Hasenfuss G, Dobrev D, Eschenhagen T, El-Armouche A (2010) Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J Clin Invest 120:617–626. doi:10.​1172/​JCI40545 PubMed
Metadaten
Titel
Constitutive phosphorylation of inhibitor-1 at Ser67 and Thr75 depresses calcium cycling in cardiomyocytes and leads to remodeling upon aging
verfasst von
Stela Florea
Ahmad Anjak
Wen-Feng Cai
Jiang Qian
Elizabeth Vafiadaki
Sarah Figueria
Kobra Haghighi
Jack Rubinstein
John Lorenz
Evangelia G. Kranias
Publikationsdatum
01.09.2012
Verlag
Springer-Verlag
Erschienen in
Basic Research in Cardiology / Ausgabe 5/2012
Print ISSN: 0300-8428
Elektronische ISSN: 1435-1803
DOI
https://doi.org/10.1007/s00395-012-0279-z

Weitere Artikel der Ausgabe 5/2012

Basic Research in Cardiology 5/2012 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.